Engineering interdisciplinary research

• Antiangiogenic therapy is aimed at stopping tumour angiogenesis (i.e. the development of the vasculature); therefore, at stopping tumour growth.
• Modern robust control algorithms provide automated drug delivery

Present and future

• In current clinical practice, there are general protocols for cancer therapies (such as chemotherapy, radiotherapy):
  • these treatments are associated with frequent and serious side effects,
  • are not cancer-specific and are not personalized to the patient,
  • Treatment costs are low but use is not optimal.
• Our concept: control-based, personalised treatment
  • these treatments have virtually no side effects,
  • it provides personalised delivery of cancer-specific (anti-angiogenic) drugs,
  • the cost of treatment is sufficiently low due to optimal drug dosing.

Model identification and controller design

• Create a mathematical tumour growth model under angiogenic inhibition, based on animal studies
• Constant and variable quasi-continuous low-dose therapy protocol
• Design optimal robust control algorithms for continuous low-dose therapy

Opening new horizons in cancer treatment

• Improve the effectiveness of cancer therapy
• Reduce treatment costs
• Minimise the side effects of therapy
• Improve the patient’s quality of life (QoL)